New method of sentinel node identification with ultrasonography using albumin as contrast agent: a study in pigs

Sentinel node detection in breast cancer using contrast‐enhanced sonography with 25% albumin—Initial clinical experience

“…However, the echo level of the surrounding fatty area hardly changes, and the resultant hypoechoic SLN is easier to identify. CEUS using microbubble, 6 albumin, 7 or a lipid-stabilized suspension of perfluorobutane microbubbles (Sonazoid, Amersham Health, Oslo, Norway) 11 has already been reported in animal studies. 12,13 However, no clinical studies of SLN detection have been reported.…”

“…We have proposed a method of SLN identification with CEUS using 25% albumin solution as the contrast agent that yielded good results in animals. 7 To our knowledge, there have been no clinical reports of CEUS as a method of identifying SLNs in cases of breast cancer. Accordingly-and encouraged by our animal study results-we conducted a clinical study on the usefulness of CEUS detection in breast cancer patients.…”

New method of sentinel node detection using a combination of contrast-enhanced ultrasound and dye guidance: an animal study

“…Goldberg et al 17 reported employing CE-US to identify SLNs, using a lipid-stabilized suspension of perfluorobutane microbubbles (Sonozoid); however, we were the first to use albumin as a contrast agent. 18 We have already proposed an SLN identification method using CE-US with albumin as the contrast agent. We have already obtained good results with this method, but because risk of infection and several other problems remaining with regard to the use of human serum, we decided to look for a replacement substance.…”

Assessment of hepatic VX2 tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging

“…Ultrasound lymphography with subcutaneous injection of ultrasound contrast material enables direct visualization of the lymphatic drainage pathways and sentinel lymph nodes of breast diseases, melanoma, etc [11][12][13][14][15] . In the present study, the traditional percutaneous hepatic injection method was used to deliver SonoVue ® microbubbles into the liver under US guidance to investigate tumor lymphangiogenesis.…”

“…However, little is known about the contrastenhanced ultrasonographic imaging used to detect tumor lymphangiogenesis. Recently, lymphosonography after interstitial injection of microbubble-based contrast agents can trace the lymphatic channels from the injection site up to the draining sentinel lymph nodes [11][12][13][14][15] . However, no report is available on lymphosonography for tumor lymphangiogenesis.…”